|
1
|
Gundrum JD, Mathiason MA, Moore DB and Go
RS: Primary testicular diffuse large B-cell lymphoma: A
population-based study on the incidence, natural history, and
survival comparison with primary nodal counterpart before and after
the introduction of rituximab. J Clin Oncol. 27:5227–5232. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moller MB, d'Amore F and Christensen BE:
Testicular lymphoma: A population-based study of incidence,
clinicopathological correlations and prognosis. The Danish Lymphoma
Study Group, LYFO. Eur J Cancer 30A. 1760–1764. 1994. View Article : Google Scholar
|
|
3
|
Shahab N and Doll DC: Testicular lymphoma.
Semin Oncol. 26:259–269. 1999.PubMed/NCBI
|
|
4
|
Menter T, Ernst M, Drachneris J, Dirnhofer
S, Barghorn A, Went P and Tzankov A: Phenotype profiling of primary
testicular diffuse large B-cell lymphomas. Hematol Oncol. 32:72–81.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fonseca R, Habermann TM, Colgan JP,
O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ
and Inwards DJ: Testicular lymphoma is associated with a high
incidence of extranodal recurrence. Cancer. 88:154–161. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bart J, Groen HJ, van der Graaf WT,
Hollema H, Hendrikse NH, Vaalburg W, Sleijfer DT and de Vries EG:
An oncological view on the blood-testis barrier. Lancet Oncol.
3:357–363. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Booman M, Douwes J, Glas AM, Riemersma SA,
Jordanova ES, Kok K, Rosenwald A, de Jong D, Schuuring E and Kluin
PM: Mechanisms and effects of loss of human leukocyte antigen class
II expression in immune-privileged site-associated B-cell lymphoma.
Clin Cancer Res. 12:2698–2705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Buskirk SJ, Evans RG, Banks PM, O'Connell
MJ and Earle JD: Primary lymphoma of the testis. Int J Radiat Oncol
Biol Phys. 8:1699–1703. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mazloom A, Fowler N, Medeiros LJ, Iyengar
P, Horace P and Dabaja BS: Outcome of patients with diffuse large
B-cell lymphoma of the testis by era of treatment: The M.D.
Anderson cancer center experience. Leuk Lymphoma. 51:1217–1224.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kridel R, Telio D, Villa D, Sehn LH,
Gerrie AS, Shenkier T, Klasa R, Slack GW, Tan K, Gascoyne RD, et
al: Diffuse large B-cell lymphoma with testicular involvement:
Outcome and risk of CNS relapse in the rituximab era. Br J
Haematol. 176:210–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
World Health Organization. The ICD-10
classification of mental behavioural disorders. Clinical
descriptions and diagnostic guidelines. (Geneva). World Health
Organization. 1992.
|
|
12
|
International Classification of Diseases
for Oncology, Third Edition, First Revision. (Geneva). World Health
Organization. 2013.
|
|
13
|
Cheah CY, Wirth A and Seymour JF: Primary
testicular lymphoma. Blood. 123:486–493. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maloney DG, Liles TM, Czerwinski DK,
Waldichuk C, Rosenberg J, Grillo-Lopez A and Levy R: Phase I
clinical trial using escalating single-dose infusion of chimeric
anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with
recurrent B-cell lymphoma. Blood. 84:2457–2466. 1994.PubMed/NCBI
|
|
15
|
Hamlin PA, Satram-Hoang S, Reyes C, Hoang
KQ, Guduru SR and Skettino S: Treatment patterns and comparative
effectiveness in elderly diffuse large B-cell lymphoma patients: A
surveillance, epidemiology, and end results-medicare analysis.
Oncologist. 19:1249–1257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tien YY, Link BK, Brooks JM, Wright K and
Chrischilles E: Treatment of diffuse large B-cell lymphoma in the
elderly: Regimens without anthracyclines are common and not futile.
Leuk Lymphoma. 56:65–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
FDA Approves Two New Indications for
Rituxan in Patients with Non-Hodgkin's Lymphoma. https://.gene.com/media/press-releases/10047/2006-09-29/fda-approves-two-new-indications-for-rit
|
|
18
|
Vitolo U, Ferreri AJ and Zucca E: Primary
testicular lymphoma. Crit Rev Oncol Hematol. 65:183–189. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hasselblom S, Ridell B, Wedel H, Norrby K,
Sender Baum M and Ekman T: Testicular lymphoma-a retrospective,
population-based, clinical and immunohistochemical study. Acta
Oncol. 43:758–765. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lagrange JL, Ramaioli A, Theodore CH,
Terrier-Lacombe MJ, Beckendorf V, Biron P, Chevreau CH,
Chinet-Charrot P, Dumont J, Delobel-Deroide A, et al: Non-Hodgkin's
lymphoma of the testis: A retrospective study of 84 patients
treated in the French anticancer centres. Ann Oncol. 12:1313–1319.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zucca E, Conconi A, Mughal TI, Sarris AH,
Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, et
al: Patterns of outcome and prognostic factors in primary
large-cell lymphoma of the testis in a survey by the International
Extranodal Lymphoma Study Group. J Clin Oncol. 21:20–27. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuper-Hommel MJ, Janssen-Heijnen ML,
Vreugdenhil G, Krol AD, Kluin-Nelemans HC, Coebergh JW and van
Krieken JH: Clinical and pathological features of testicular
diffuse large B-cell lymphoma: A heterogeneous disease. Leuk
Lymphoma. 53:242–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bacon CM, Ye H, Diss TC, McNamara C, Kueck
B, Hasserjian RP, Rohatiner AZ, Ferry J, Du MQ and Dogan A: Primary
follicular lymphoma of the testis and epididymis in adults. Am J
Surg Pathol. 31:1050–1058. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang DN, Yang ZR, Wang WY, Zhao S, Yang
QP, Tang Y, Bi CF and Liu WP: Extranodal nasal type natural
killer/T-cell lymphoma of testis: Report of seven cases with review
of literature. Leuk Lymphoma. 53:1117–1123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roychoudhuri R, Putcha V and Møller H:
Cancer and laterality: A study of the five major paired organs
(UK). Cancer Causes Control. 17:655–662. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cao B, Ji DM, Zhou XY, Zhao TP, Guo Y,
Wang ZH, Cao JN, Hu XC and Hong XN: A clinical analysis of primary
testicular diffuse large B-cell lymphoma in China. Hematology.
16:291–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Li ZM, Huang JJ, Xia Y, Li H, Li
YJ, Zhu YJ, Zhao W, Xia XY, Wei WX, et al: Three prognostic factors
influence clinical outcomes of primary testicular lymphoma. Tumour
Biol. 34:55–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Coiffier B, Lepage E, Briere J, Herbrecht
R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,
Gaulard P, et al: CHOP chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pfreundschuh M, Trümper L, Osterborg A,
Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani
PL, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like
chemotherapy alone in young patients with good-prognosis diffuse
large-B-cell lymphoma: A randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pfreundschuh M, Schubert J, Ziepert M,
Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M,
Peter N, et al: Six versus eight cycles of bi-weekly CHOP-14 with
or without rituximab in elderly patients with aggressive CD20+
B-cell lymphomas: A randomised controlled trial (RICOVER-60).
Lancet Oncol. 9:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sehn LH, Donaldson J, Chhanabhai M,
Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli
JJ, Sutherland J, et al: Introduction of combined CHOP plus
rituximab therapy dramatically improved outcome of diffuse large
B-cell lymphoma in British Columbia. J Clin Oncol. 23:5027–5033.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Avilés A, Nambo MJ, Cleto S, Neri N and
Huerta-Guzmán J: Rituximab and dose-dense chemotherapy in primary
testicular lymphoma. Clin Lymphoma Myeloma. 9:386–389. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Batchelor TT, Grossman SA, Mikkelsen T, Ye
X, Desideri S and Lesser GJ: Rituximab monotherapy for patients
with recurrent primary CNS lymphoma. Neurology. 76:929–930. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mappa S, Marturano E, Licata G, Frezzato
M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Soraru M,
Vianello F, et al: Salvage chemoimmunotherapy with rituximab,
ifosfamide and etoposide (R-IE regimen) in patients with primary
CNS lymphoma relapsed or refractory to high-dose methotrexate-based
chemotherapy. Hematol Oncol. 31:143–150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rubenstein JL, Combs D, Rosenberg J, Levy
A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, et al:
Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal
compartment. Blood. 101:466–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kemmerling R, Stintzing S, Mühlmann J,
Dietze O and Neureiter D: Primary testicular lymphoma: A strictly
homogeneous hematological disease? Oncol Rep. 23:1261–1267.
2010.PubMed/NCBI
|
